Latest Breaking News On - விசுவாசமான பள்ளத்தாக்கு மூலதனம் - Page 1 : comparemela.com

Photo: Pixabay April 22, 2021 Chinese genome editing startup EdiGene Inc has secured 400 million yuan ($61.7 million) in a Series B+ round of financing led by private equity (PE) firm Loyal Valley Capital to advance its pipeline into clinics and to scale up the business operation. The Series B+ round roped in new investors BioTrack Capital and Sherpa Healthcare Partners, two China-focused, healthcare venture capital (VC) companies. The firm’s existing investors including IDG Capital, Lilly Asia Venture, 3H Health Investment, Huagai Capital, Sequoia Capital China, Alwin Capital, and Kunlun Capital re-upped in the deal. Founded in 2015, EdiGene is a clinical-stage biotech company that focuses on leveraging genome editing technologies to accelerate drug discovery and to develop novel therapeutics for a broad range of genetic diseases and cancer. The startup has established its proprietary 

United statesAsia pacificRandy linChina national medical products administrationH health investmentEdigene incLoyal valley capitalBiotrack capitalSherpa healthcare partnersLilly asia ventureHealth investmentHuagai capitalSequoia capital chinaAlwin capitalKunlun capitalNorth america